Clinical Trial

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

Recruiting
View on ClinicalTrials.gov →
Summary
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-17.
Trial Details
NCT Number NCT07369596
Lead Sponsor University of Malaya
Conditions Non Small Cell Lung Carcinoma NSCLC
Enrollment 150 participants
Start Date 2026-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02